Liver biopsies obtained at pretreatment and 24 weeks, 3 years, and 5 years post-treatment revealed that 50% of patients experienced histological improvement, with notable reductions in steatosis, inflammation, and fibrosis stage, indicating a favorable impact of SGLT2 inhibition therapy on NAFLD in T2DM patients over 5 years [20]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.